Siemens Healthcare Diagnostics Gmbh

Dade Behring Inc.

Tie Q Wei

Zhu Teng

Manoj Sharma

Alan Robert Craig

Martin A Drinan

Amy Posey

Jie Li

Christy Schaible

Izak Bahar

Yi Feng Zheng

Carsten Schelp

Victor P Chu

Qimu Liao

David R Hudson

Tatiana Mareeva

Jeffrey L Moore

Yun Yue

Gary Hickey

Chengrong X Wang

Thomas John Pankratz

William D Bedzyk

Yuriy Smirnov

Gerald Siefring, Jr

James Floyd Pierson-Perry

Connie Mary Sanders

Xiaodong Liu

Gerald Siefring

Elsa Garcia

Chengrong Wang

The present invention relates to methods and compositions to remove or reduce biotin interference from certain assays.

Methods and compositions for removing biotin interference from assays using molecular traps

Methods of detecting and flagging and/or suppressing aberrant results caused by incomplete dispersion of an immunoassay reagent used in a turbidimetric immunoassay are disclosed.

Methods for detection of aberrant results caused by incomplete dispersion of immunoassay reagent

Kits containing a chemiluminescent detection system and microfluidics devices and methods for determining the concentration of biotin in a sample are disclosed. The kits, microfluidics devices, and methods utilize a sensitizer capable of generating singlet oxygen in its excited state and having avidin or an analog thereof directly or indirectly bound thereto, as well as a singlet oxygen-activatable chemiluminescent compound having biotin or an analog thereof directly or indirectly bound thereto.

Kits, microfluidics devices, and methods for performing biotin assays

Methods and reagents are disclosed for minimizing a false result in an assay measurement for determining a concentration of an analyte in a sample suspected of containing the analyte. The method comprises pretreating both an antibody and a sample to be subjected to a non-agglutination immunoassay. In the method the antibody and the sample are combined with a pretreatment agent selected from the group consisting of hydroxyphenyl-substituted C1-C5 carboxylic acids and metallic salts thereof and halogen-substituted C1-C5 carboxylic acids and metallic salts thereof in an amount effective to enhance the accuracy of the non-agglutination immunoassay.

Pretreatment agent in non-agglutination assays

Kits containing a multiplexed chemiluminescent detection system and microfluidics devices and methods for detecting the presence and/or concentration of biotin and at least one target analyte in a sample are disclosed. The kits, microfluidics devices, and methods utilize singlet oxygen-activatable chemiluminescent compounds in combination with two or more fluorescent molecules that emit light at different wavelengths.

Compositions, kits, and methods for multiplex assays to correct for biotin interference in target analyte measurements

Methods and compositions for removing biotin interference from assays using conjugated molecular traps

Methods of mitigating lipoprotein interference in in vitro diagnostic assays for target hydrophobic analytes are disclosed, as well as compositions, kits, and devices useful in said methods. A pretreatment reagent is utilized that includes at least one enzyme that digests lipoprotein.

Compositions, devices, and methods of mitigating lipoprotein interference in in vitro diagnostic assays for hydrophobic analytes

The present disclosure includes compounds, kits, and assay procedures for use in determining the levels of certain types of drugs in samples that contain specific binding proteins for the drugs. The present disclosure includes analog compounds useful for displacing the drugs from their endogenous binding proteins, and kits including same, as well as methods that utilize these displacers as binding competitors in pharmaceutical assays.

Binding competitors for use in macrophilin-binding pharmaceutical assays and methods of use thereof

Methods are disclosed for a sandwich assay for a small molecule having a molecular weight of about 500 to about 2,500. The method comprises the use of a first antibody that binds to the small molecule and a second antibody that binds to the small molecule at a portion of the small molecule other than a portion to which the first antibody binds. The second antibody is prepared from an immunogen that comprises a hapten that is not the small molecule or a derivative of the small molecule wherein the hapten comprises a moiety that is structurally similar to that of the second portion of the small molecule. The antibodies may be employed in sandwich assays for the small molecule.

Sandwich assay for small molecules

Methods are disclosed of designing antibodies for a sandwich assay for a small molecule having a molecular weight of about 500 to about 2,000. The method comprises preparing a first antibody that binds to the small molecule, and preparing a second antibody that binds to the small molecule at a portion of the small molecule other than a portion to which the first antibody binds. The second antibody is prepared from an immunogen that comprises a predetermined portion of the small molecule. The antibodies may be employed in sandwich assays for the small molecule.

Sandwich assay design for small molecules

The present invention discloses compositions that comprise compounds relating to vitamin D. These compounds are useful for assays in the determination and distinguishing of certain 3-epimeric 25 hydroxyvitamin D and non-epimeric 25 hydroxyvitamin D. The compositions of the present invention may be used for example as immunogens used to develop antibodies to certain vitamin D compounds or conjugates used in assays for certain vitamin D compounds or used as a solid phase reagent in assays. The composition comprises a compound of one or more of the generic formula (R)-(L)-Z.

Compositions relating to vitamin D

Growing community of inventors

Wilmington, DE, United States of America

Tie Q Wei